Your browser doesn't support javascript.
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Horby, Peter; Staplin, Natalie; Haynes, Richard; Landray, Martin.
  • Horby P; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK. Electronic address: peter.horby@ndm.ox.ac.uk.
  • Staplin N; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Haynes R; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Landray M; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Lancet ; 398(10297): 300, 2021 07 24.
Article in English | MEDLINE | ID: covidwho-1322401
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article